Summary: Evaluated chlorthalidone versus amlodipine versus lisinopril in patients with hypertension and coronary risk factors. The primary composite endpoint of fatal coronary heart disease or nonfatal MI was similar in the three groups. Chlorthalidone improved blood pressure the best, reduced stroke, cardiovascular disease and heart failure better than lisinopril, and reduced heart failure diagnosis better than amlodipine. Only 30% of patients achieved goal blood pressure control on one agent. There was a doxazosin arm which was stopped early due to an increase in the primary endpoint and twice the risk of developing heart failure versus chlorthalidone. A subgroup evaluated pravastatin 40 mg PO daily which did not show any mortality benefit despite lowering LDL cholesterol levels (small study).
JAMA. 2002 Dec 18;288(23):2981-97.
Eponym: The Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial